HemaSphere (Jun 2022)

PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL

  • H. Wang,
  • Q. He,
  • R. Zhao,
  • L. Xie,
  • J. Ma,
  • C. Liu,
  • K. Lu,
  • H. Wei,
  • D. Liu,
  • L. Xing,
  • X. Deng,
  • Z. Sun,
  • X. Chu,
  • N. Gao,
  • Y. Zhong,
  • Y. Sun,
  • H. Zhang,
  • H. Zhang,
  • W. Xu,
  • Z. Li

DOI
https://doi.org/10.1097/01.HS9.0000851148.10454.66
Journal volume & issue
Vol. 6
pp. 1950 – 1951

Abstract

Read online

No abstracts available.